Light-Activated Nanoparticles Shrink Tumors in Mice
Penn State researchers report a light-triggered gold-and-silver nanoparticle system that releases a therapeutic microRNA at illuminated tumor sites.
Updated on Nov. 20, 2026 in Cancer

Penn State researchers developed nanoparticles made of gold and silver layers that release the microRNA-20a-5p only when exposed to near-infrared light. In mice with tumors from human hypopharyngeal cancer cells, illuminated tumor volume fell about 95 percent within 48 hours, while unilluminated tumors continued to grow.
Why it matters
The approach aims to deliver therapeutic molecules to intended locations without accumulating in healthy organs, a persistent challenge in cancer treatment. The findings are at an extremely early stage, and the system is not yet ready for clinical use.
The evidence comes from a preclinical mouse study comparing illuminated and non-illuminated tumors derived from human hypopharyngeal cancer cells. Illuminated tumor volume fell roughly 95 percent within 48 hours, while untreated tumors kept growing, but extensive safety testing has not yet been reported.
The players
Penn State
The Pennsylvania State University is a public research university whose researchers developed the light-activated nanoparticle system.
Illuminate Therapeutics
Illuminate Therapeutics is the company that licensed the Penn State nanoparticle technology through the university's LADDR platform.
The details
The nanoparticles convert near-infrared light into localized heat, which triggers release of the microRNA cargo at the illuminated site. The study was published in the Journal of Biomedical Materials Research, and Penn State has licensed the technology to Illuminate Therapeutics through its LADDR platform.
Timeline
The study was published in the Journal of Biomedical Materials Research; the publication date was not provided.
Tumor volume reduction was measured within 48 hours of illumination in the mouse study.
The Big Picture
The Penn State LADDR platform is the pathway that moved this nanoparticle technology from university lab to licensed company. The light-triggered approach extends a broader effort to deliver microRNA therapeutics selectively, but it remains years from any clinical application.
For patients, this work does not yet change available treatment options, since it has only been tested in mice. Any future therapy would require extensive safety testing and clinical trials before it could reach people.
The takeaway
Light-triggered drug delivery could one day limit therapy to diseased tissue, reducing damage to healthy organs. Readers should treat these early mouse results as a promising step rather than a available treatment.
Further reading
Explore more Cancer research and treatment developments.
Source note: This article includes information reported by Drug Target Review.






